OUTCOMES OF CORNEAL ALLERGENIC INTRASTROMAL RING SEGMENT (CAIRS) SURGERY
Dr David Gunn, Ophthalmologist
Cornea, Cataract and Refractive Surgeon, Queensland Eye Institute
& Focus Vision Clinic in Brisbane, Queensland
RESEARCHER PROFILE (Filmed in Brisbane, Queensland, Australian | June 2024)
Dr David Gunn is an ophthalmologist specialising in cornea, cataract, and refractive surgery at the Queensland Eye Institute and Focus Vision in Brisbane, Queensland. His journey into ophthalmology began during medical school, inspired by a mentor. He initially engaged in research on mouse glaucoma, exploring amacrine cells and their responses.
After completing his residency and gaining experience in eye casualty at the Royal Brisbane Hospital, David underwent four years of surgical training in the Queensland network. This was followed by a stint at the Bristol Eye Hospital in the UK, focusing on the cornea and anterior segment. Since returning to Queensland, he has concentrated on keratoconus research.
One of the pivotal moments in his career was the decision to specialise in cornea surgery, which included performing Australia’s first CAIRS procedure in May 2021. His current research examines outcomes for patients undergoing Corneal Allergenic Intrastromal Ring Segment (CAIRS) surgery.
Dr Gunn finds immense satisfaction in the immediate post-operative results he sees in patients, as visual acuity provides a tangible measure of success. He is passionate about introducing less invasive surgical techniques that lead to improvements in patients’ lives.
-
Better biomarkers for predicting the incidence of having atherosclerosis and heart attack
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
-
Professor Alex Fornito
PROFESSOR ALEX FORNITO
HEAD OF THE BRAIN MAPPING AND MODELLING RESEARCH PROGRAM
TURNER INSTITUTE FOR BRAIN AND MENTAL HEALTH, MONASH UNIVERSITY
VICTORIA, AUSTRALIA -
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
